TAMPA, Fla. – Midgut neuroendocrine tumors are a rare type of cancer that develops in the small intestine and colon. Roughly 12,000 people are diagnosed with this disease each year. In January, the United Stated Food and Drug Administration approved Lutathera, a first-of-its-kind peptide receptor radionuclide therapy. The injection consists of a somatostatin analog combined with a radioactive isotope that directly targets neuroendocrine tumor cells.
Dr. Jonathan Strosberg, head of Neuroendocrine Tumor Program at Moffitt “Treatment options have been limited for patients with neuroendocrine tumors and toxicities of treatment can often outweigh the benefit. Our studies have shown Lutathera is an effective option to treat tumor progression and also provide patients with a better quality of life,” said Jonathan R. Strosberg, M.D., head of the Neuroendocrine Tumor Program at Moffitt Cancer Center.
The Journal of Clinical Oncology published new data from the NETTER-1 clinical trial highlighting the impact of Lutathera on patients’ quality of life. Strosberg notes the importance of this issue, given the relatively long durations of treatments and overall survival compared to other malignancies. The results showed that treatment with Lutathera provides significantly longer time to deterioration of quality of life for patients compared to those treated
Article originally posted at